secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0001193125-24-174317
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte appoints John P. Furey to Board of Directors, effective July 2, 2024
----------------------------------------------------------------------------

- John P. Furey appointed as Class II director; term expires at 2025 annual meeting.
- Furey received initial stock option valued at $800,000 vested over 36 months; also joins Compensation Committee.
- Annual equity awards of $450,000 (75% option, 25% RSU) and cash retainers of $50,000 board / $7,500 committee.
- Indemnification agreement executed; Furey qualifies as independent director under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000119312524174317/0001193125-24-174317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000119312524174317/d781953d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-174317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer